

Disclosures

Personal Commercial (20)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AstraZeneca	Research/Research Grants	Significant (>= \$5,000)	<i>Vascular Medicine General Cardiology Heart Failure and Cardiomyopathies</i>
AstraZeneca	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Vascular Medicine General Cardiology Heart Failure and Cardiomyopathies</i>
Boeinger Ingelheim	Research/Research Grants	Significant (>= \$5,000)	<i>Vascular Medicine General Cardiology Heart Failure and Cardiomyopathies</i>
Bristol-Myers Squibb Company	Research/Research Grants	Significant (>= \$5,000)	<i>Vascular Medicine General Cardiology Heart Failure and Cardiomyopathies</i>
Bristol-Myers Squibb Company	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Vascular Medicine General Cardiology Heart Failure and Cardiomyopathies</i>
CellProthera	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Eli-Lilly, Roche	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
GlaxoSmithKline	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology</i>
GlaxoSmithKline	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
ICTargets	Research/Research Grants <i>‡ MEMRI and mangafodipir</i>	None (\$0)	<i>Noninvasive Imaging</i>
Inositec	Research/Research Grants	Modest (< \$5,000)	<i>Valvular Heart Disease</i>
Jansen	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Acute Coronary Syndromes</i>
Life Molecular Imaging	Research/Research Grants <i>‡ iThrombus and BioThrombus</i>	None (\$0)	<i>Noninvasive Imaging</i>
Merck & Co., Inc.	Research/Research Grants	Significant (>= \$5,000)	<i>Vascular Medicine General Cardiology Heart Failure and Cardiomyopathies</i>
Oncoarendi	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP</i>
Pfizer	Research/Research Grants	Significant (>= \$5,000)	<i>Vascular Medicine General Cardiology Heart Failure and Cardiomyopathies</i>
Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Vascular Medicine General Cardiology Heart Failure and Cardiomyopathies</i>
Reckitt Benckiser Pharmaceuticals Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
Toshiba	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Noninvasive Imaging</i>
UCB Inc.	Data Safety Monitoring Board	Modest (< \$5,000)	<i>General Cardiology</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (9)

Trial Name	Trial Sponsor	Trial Funding Source
STRENGTH	AstraZeneca Pharmaceuticals	AstraZeneca Pharmaceuticals
DAPA-MI	AstraZeneca Pharmaceuticals	
CV019-010	Bristol-Myers Squibb Company	
CV013020	Bristol-Myers Squibb Company	Bristol-Myers Squibb Company

Trial Name	Trial Sponsor	Trial Funding Source
CV016007	Bristol-Myers Squibb Company	Bristol-Myers Squibb Company
EXCELLENT	CellProthera	CellProthera
CLEAR Outcomes	Esperion	Esperion
LRP Trial	Infraredx	Infraredx
ORION	Novartis Corporation	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
Self				
2010	Vioxx claims for CV events	Defendant	Acting as an expert witness for MSD in defence of claims related to Vioxx in Scotland, UK.	Modest (< \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 11/19/2025
 URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 11/19/2025
 URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 11/19/2025
 URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 11/19/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.